Instil Bio and ImmuneOnco outline global registrational strategy for SYN-2510 in NSCLC and TNBC

Instil Bio, Inc.

Global registrational strategy for SYN-2510/IMM2510 in front-line NSCLC and TNBC announced.
Phase 1b/2 chemo combo in front-line NSCLC expected to start late 2024 in China; US IND submission for SYN-2510 targeted late 2024 for Phase 2 monotherapy in second-line NSCLC.
Phase 1b/2 chemo combo in front-line TNBC expected to start early 2025 in China; potential global Phase 3 trials after proof-of-concept.
US Phase 2 monotherapy trial in second-line NSCLC expected to support efficient enrollment of global Phase 3 studies.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.